GeneThera, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTHR research report →
Companywww.genethera.net
GeneThera, Inc. , a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.
- CEO
- Antonio Milici
- IPO
- 2012
- Employees
- 2
- HQ
- Westminster, CO, US
Price Chart
Valuation
- Market Cap
- $3.53K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 12.75%
- ROIC
- 13.71%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,011,000 · -30.62%
- EPS
- $-0.04 · -0.50%
- Op Income
- $-1,009,000
- FCF YoY
- -61.48%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.81
- Avg Volume
- 2.94K
Get TickerSpark's AI analysis on GTHR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 11 | Kolesnikov Avel | other | 0 |
| Jan 4, 12 | MILICI ANTONIO | buy | 6,400,000 |
| Dec 31, 11 | IRIZARRY TANNYA L | buy | 2,690,000 |
| Jan 4, 12 | MILICI ANTONIO | buy | 6,400,008 |
| Feb 25, 08 | McNece Elmer Roy Jr | buy | 200,000 |
| Feb 19, 08 | McNece Elmer Roy Jr | buy | 135,000 |
| Jan 17, 08 | McNece Elmer Roy Jr | buy | 6,000 |
| Jan 15, 08 | McNece Elmer Roy Jr | buy | 50,000 |
| Jan 22, 08 | McNece Elmer Roy Jr | sell | 20,000 |
| Jan 15, 08 | McNece Elmer Roy Jr | buy | 100,000 |
Our GTHR Coverage
We haven't published any research on GTHR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GTHR Report →